These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 23930673)

  • 21. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
    Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
    Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid detection of the irinotecan-related UGT1A1 & 5-fluorouracil related DPYD polymorphism by asymmetric polymerase chain reaction melting curve analysis.
    Lian J; Liang Y; Wang Y; Chen Y; Li X; Xia L
    Clin Chim Acta; 2024 Jul; 561():119761. PubMed ID: 38848897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Deligonul A; Aksoy S; Tezcan G; Tunca B; Kanat O; Cubukcu E; Yilmazlar T; Ozturk E; Egeli U; Cecener G; Alemdar A; Evrensel T
    Genet Test Mol Biomarkers; 2021 Apr; 25(4):276-283. PubMed ID: 33877893
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
    Negarandeh R; Salehifar E; Saghafi F; Jalali H; Janbabaei G; Abdhaghighi MJ; Nosrati A
    BMC Cancer; 2020 Jun; 20(1):560. PubMed ID: 32546132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
    Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
    Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
    Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
    Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
    Rosmarin D; Palles C; Church D; Domingo E; Jones A; Johnstone E; Wang H; Love S; Julier P; Scudder C; Nicholson G; Gonzalez-Neira A; Martin M; Sargent D; Green E; McLeod H; Zanger UM; Schwab M; Braun M; Seymour M; Thompson L; Lacas B; Boige V; Ribelles N; Afzal S; Enghusen H; Jensen SA; Etienne-Grimaldi MC; Milano G; Wadelius M; Glimelius B; Garmo H; Gusella M; Lecomte T; Laurent-Puig P; Martinez-Balibrea E; Sharma R; Garcia-Foncillas J; Kleibl Z; Morel A; Pignon JP; Midgley R; Kerr D; Tomlinson I
    J Clin Oncol; 2014 Apr; 32(10):1031-9. PubMed ID: 24590654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
    Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
    Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
    Hamzic S; Schärer D; Offer SM; Meulendijks D; Nakas C; Diasio RB; Fontana S; Wehrli M; Schürch S; Amstutz U; Largiadèr CR
    Br J Clin Pharmacol; 2021 Aug; 87(8):3234-3243. PubMed ID: 33491253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (
    Nguyen DG; Morris SA; Hamilton A; Kwange SO; Steuerwald N; Symanowski J; Moore DC; Hanson S; Mroz K; Lopes KE; Larck C; Musselwhite L; Kadakia KC; Koya B; Chai S; Osei-Boateng K; Kalapurakal S; Swift K; Hwang J; Patel JN
    JCO Precis Oncol; 2024 Jun; 8():e2300623. PubMed ID: 38935897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
    Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
    Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Madi A; Fisher D; Maughan TS; Colley JP; Meade AM; Maynard J; Humphreys V; Wasan H; Adams RA; Idziaszczyk S; Harris R; Kaplan RS; Cheadle JP
    Eur J Cancer; 2018 Oct; 102():31-39. PubMed ID: 30114658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
    Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
    Shakeel F; Fang F; Kwon JW; Koo K; Pasternak AL; Henry NL; Sahai V; Kidwell KM; Hertz DL
    Pharmacogenomics; 2021 Feb; 22(3):145-155. PubMed ID: 33410339
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.